Market Cap 105.76B
Revenue (ttm) 48.30B
Net Income (ttm) -8.95B
EPS (ttm) N/A
PE Ratio 7.77
Forward PE 7.79
Profit Margin -18.53%
Debt to Equity Ratio 2.63
Volume 15,667,600
Avg Vol 16,824,885
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 93%
Beta 0.29
Analysts Sell
Price Target $53.13

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:29 AM
Actionable Trade Alert for $BMY: Market Context: $BMY is currently trading at $51.95, showing strength as it approaches its 60D high of $52.08. The RSI at 64.04 indicates bullish momentum, but it is nearing overbought territory. The MA30 and MA50 are both below the current price, suggesting a strong upward trend. Directional Bias: The price is above both the MA30 (46.91) and MA50 (45.92), reinforcing a bullish sentiment. The recent high-low range indicates potential for further upside, with a clear resistance at $52.08. Trade Plan: - Suggested Entry: $51.95 - Stop Loss: $49.50 (approx. 4.7% below entry) - Take Profit Targets: 1. $53.00 (2.0% gain) 2. $54.00 (3.5% gain) 3. $60.00 (15.6% gain) The third target provides a potential ROI of over 17%. Monitor the trade closely, especially around resistance levels. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 5 at 7:55 PM
Enter: $BMY Calls Strike Price: $52 Expiry Date: DEC 26 2025 Buy in Price: $1.19 - $1.25 Sell Price: $2.39 Profit : +101% (Turn every $1 into $2.01) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 7:40 PM
Big win for $BMY’s CAR T lineup — this could reshape the sales trajectory. Bristol Myers just secured FDA approval to expand Breyanzi’s label to R/R marginal zone lymphoma, strengthening its CAR T portfolio at a time when sales are already on the rise. Full breakdown here 👉 https://www.zacks.com/stock/news/2800307/will-breyanzis-label-expansion-boost-bmys-car-t-cell-therapy-sales?cid=sm-stocktwits-2-2800307-teaser-23727&ADID=SYND_STOCKTWITS_TWEET_2_2800307_TEASER_23727
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 6:40 PM
$BMY: FDA approval makes Breyanzi the only CAR T cell therapy approved for 5 cancer types! 🧬 💥 Sales skyrocketed 100% to $966M in the first nine months of 2025, driven by new indications and strong growth in LBCL. 📉 Shares down 8.2% YTD but trading at a discount with an 8.63x forward P/E vs. industry’s 16.95x. Discover the full story here 👉 https://www.zacks.com/stock/news/2800307/will-breyanzis-label-expansion-boost-bmys-car-t-cell-therapy-sales?cid=sm-stocktwits-2-2800307-body-23714&ADID=SYND_STOCKTWITS_TWEET_2_2800307_BODY_23714
0 · Reply
huskyd97
huskyd97 Dec. 5 at 6:35 PM
$BMY lets get to 70 by march
0 · Reply
RunnerSignals
RunnerSignals Dec. 5 at 3:06 PM
$RBRK $COO $AEO $BMY clearing resistance like pros volume buzzing and momentum building
0 · Reply
peloswing
peloswing Dec. 5 at 2:15 PM
$BMY up 14%+ since our last chart!
0 · Reply
FRthDKSD
FRthDKSD Dec. 5 at 12:07 PM
$BMY undervalued bigly
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 5 at 3:57 AM
$BMY Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) "In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the most of any CD19-directed CAR T cell therapy"
0 · Reply
JustAnotherGuy007
JustAnotherGuy007 Dec. 5 at 2:10 AM
$BMY Breyanzi Approved by the FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma
0 · Reply
Latest News on BMY
Do These 3 Healthcare Stocks Need a Checkup?

Dec 5, 2025, 4:05 PM EST - 23 hours ago

Do These 3 Healthcare Stocks Need a Checkup?

MRK PFE


What Is Happening With BMY Stock?

Dec 1, 2025, 9:50 AM EST - 5 days ago

What Is Happening With BMY Stock?


2 Top Dividend Stocks to Buy and Hold

Nov 30, 2025, 4:05 AM EST - 6 days ago

2 Top Dividend Stocks to Buy and Hold

JNJ


Bristol Myers Squibb to Host Hematology-Focused Investor Event

Nov 24, 2025, 6:59 AM EST - 12 days ago

Bristol Myers Squibb to Host Hematology-Focused Investor Event


Bristol Myers, Sanofi sued by Texas over Plavix

Nov 20, 2025, 4:06 PM EST - 15 days ago

Bristol Myers, Sanofi sued by Texas over Plavix

SNY


This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.

Nov 20, 2025, 8:00 AM EST - 16 days ago

This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.


Why Bristol-Myers Squibb Remains Undervalued In 2025

Nov 18, 2025, 9:26 AM EST - 18 days ago

Why Bristol-Myers Squibb Remains Undervalued In 2025


Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 22 days ago

Bristol Myers, J&J halt heart drug trial after interim review

JNJ


Update on Phase 3 Librexia ACS Trial

Nov 14, 2025, 6:59 AM EST - 22 days ago

Update on Phase 3 Librexia ACS Trial


3 Healthcare Stocks Topping a 2025 List of Dividend Yields

Nov 12, 2025, 8:27 PM EST - 23 days ago

3 Healthcare Stocks Topping a 2025 List of Dividend Yields

PFE XRAY


Final Trade: UNH, OIH, AMD, BMY

Nov 11, 2025, 6:28 PM EST - 24 days ago

Final Trade: UNH, OIH, AMD, BMY

AMD OIH UNH


Bristol-Myers Squibb: Way Too Cheap At 7x P/E

Nov 4, 2025, 8:00 AM EST - 4 weeks ago

Bristol-Myers Squibb: Way Too Cheap At 7x P/E


PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 1:29 AM
Actionable Trade Alert for $BMY: Market Context: $BMY is currently trading at $51.95, showing strength as it approaches its 60D high of $52.08. The RSI at 64.04 indicates bullish momentum, but it is nearing overbought territory. The MA30 and MA50 are both below the current price, suggesting a strong upward trend. Directional Bias: The price is above both the MA30 (46.91) and MA50 (45.92), reinforcing a bullish sentiment. The recent high-low range indicates potential for further upside, with a clear resistance at $52.08. Trade Plan: - Suggested Entry: $51.95 - Stop Loss: $49.50 (approx. 4.7% below entry) - Take Profit Targets: 1. $53.00 (2.0% gain) 2. $54.00 (3.5% gain) 3. $60.00 (15.6% gain) The third target provides a potential ROI of over 17%. Monitor the trade closely, especially around resistance levels. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 5 at 7:55 PM
Enter: $BMY Calls Strike Price: $52 Expiry Date: DEC 26 2025 Buy in Price: $1.19 - $1.25 Sell Price: $2.39 Profit : +101% (Turn every $1 into $2.01) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 7:40 PM
Big win for $BMY’s CAR T lineup — this could reshape the sales trajectory. Bristol Myers just secured FDA approval to expand Breyanzi’s label to R/R marginal zone lymphoma, strengthening its CAR T portfolio at a time when sales are already on the rise. Full breakdown here 👉 https://www.zacks.com/stock/news/2800307/will-breyanzis-label-expansion-boost-bmys-car-t-cell-therapy-sales?cid=sm-stocktwits-2-2800307-teaser-23727&ADID=SYND_STOCKTWITS_TWEET_2_2800307_TEASER_23727
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 6:40 PM
$BMY: FDA approval makes Breyanzi the only CAR T cell therapy approved for 5 cancer types! 🧬 💥 Sales skyrocketed 100% to $966M in the first nine months of 2025, driven by new indications and strong growth in LBCL. 📉 Shares down 8.2% YTD but trading at a discount with an 8.63x forward P/E vs. industry’s 16.95x. Discover the full story here 👉 https://www.zacks.com/stock/news/2800307/will-breyanzis-label-expansion-boost-bmys-car-t-cell-therapy-sales?cid=sm-stocktwits-2-2800307-body-23714&ADID=SYND_STOCKTWITS_TWEET_2_2800307_BODY_23714
0 · Reply
huskyd97
huskyd97 Dec. 5 at 6:35 PM
$BMY lets get to 70 by march
0 · Reply
RunnerSignals
RunnerSignals Dec. 5 at 3:06 PM
$RBRK $COO $AEO $BMY clearing resistance like pros volume buzzing and momentum building
0 · Reply
peloswing
peloswing Dec. 5 at 2:15 PM
$BMY up 14%+ since our last chart!
0 · Reply
FRthDKSD
FRthDKSD Dec. 5 at 12:07 PM
$BMY undervalued bigly
0 · Reply
AlertsAndNews
AlertsAndNews Dec. 5 at 3:57 AM
$BMY Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) "In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the most of any CD19-directed CAR T cell therapy"
0 · Reply
JustAnotherGuy007
JustAnotherGuy007 Dec. 5 at 2:10 AM
$BMY Breyanzi Approved by the FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma
0 · Reply
frankster
frankster Dec. 5 at 12:39 AM
$BMY broke the 50 now question is if this is beginning of the run to 70+ or we go right back down with the next headline.
1 · Reply
Zonata
Zonata Dec. 4 at 9:00 PM
$BMY sold, another 15%. Second time I swing this. GL to all... I'll revisit if it dumps.
0 · Reply
JarvisFlow
JarvisFlow Dec. 4 at 8:01 PM
Scotiabank has updated their rating for Bristol-Myers Squibb ( $BMY ) to Sector Perform with a price target of 53.
0 · Reply
juice_rock
juice_rock Dec. 4 at 7:33 PM
$BMY We have 35 Phase 3's and all it takes is one good data release...
0 · Reply
Rich_P
Rich_P Dec. 4 at 7:00 PM
$BMY Don’t worry just “Shake it Off”.
0 · Reply
Alphasearch
Alphasearch Dec. 4 at 6:37 PM
$BMY Hitting 26 week high after double pivoting yesterday. Stock is still almost 19% below the tariff drop and major resistance at the 200 week of $58.87. But as I have posted hundreds of times that when a stock clears its most recent highest high Anchored VWAP sentiment changes and stocks typically go higher as buyers since are in the green. In this case it was this week clearing the March 10 high AVWAP of $48.16. This is the average since hitting a high that week of $63.33. Holding large position
0 · Reply
hadababymama
hadababymama Dec. 4 at 6:34 PM
$BMY straight up to $55
0 · Reply
ZacksResearch
ZacksResearch Dec. 4 at 6:32 PM
$BMY pops on Alzheimer’s news — but is this surge justified with data pushed to next year? The move comes after the company chose to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, which also delays the readout into next year. Clear catalyst now, bigger question mark later. Full breakdown here 👉 https://www.zacks.com/stock/news/2799650/bmy-gains-on-news-of-continuation-of-alzheimers-disease-study?cid=sm-stocktwits-2-2799650-teaser-23546&ADID=SYND_STOCKTWITS_TWEET_2_2799650_TEASER_23546
1 · Reply
wheresdannynow
wheresdannynow Dec. 4 at 5:40 PM
$226B immunotherapy sector up 13%/yr: $MRK +$BMY dominate, $IOVA TIL approved, $ANIX up 80% YTD. $BIOV DPX just proved best-in-class neoantigen delivery in the same wave.
0 · Reply
ZacksResearch
ZacksResearch Dec. 4 at 5:32 PM
$BMY shares jump 5.62% — what sparked the rally? 🚀 The continuation of the phase III ADEPT-2 study on Cobenfy surprised many, easing fears of a potential failure announcement. Despite a YTD loss of 9.9%, this decision appeased investors. See the full analysis here 👉 https://www.zacks.com/stock/news/2799650/bmy-gains-on-news-of-continuation-of-alzheimers-disease-study?cid=sm-stocktwits-2-2799650-body-23523&ADID=SYND_STOCKTWITS_TWEET_2_2799650_BODY_23523
0 · Reply
shalombi
shalombi Dec. 4 at 3:57 PM
$BMY $62🧲
0 · Reply
vanguard100
vanguard100 Dec. 4 at 3:51 PM
0 · Reply